HF Patients With LAVDs Being Treated With SGLT2i

• Status: Not yet recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure patients with left ventricular assist devices (LVAD).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago

Criteria

Inclusion Criteria:

1. LVAD implantation

2. Have not already been prescribed management with an SGLT2i

3. Estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m2

4. Age ≥ 18 years-old

5. Able to provide informed consent

Exclusion Criteria:

1. Diagnosis of Type 1 DM

2. eGFR < 30 ml/min/1.73 m2

3. Age < 18 years-old